This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ebola Tablet Vaccine

Vaxart, Inc.

Drug Names(s): Ebola Tablet Vaccine Program

Description: Vaxart’s Ebola vaccine candidate is based on the company's oral vaccine delivery platform, which includes a non-replicating adenovirus type 5 (Ad5) that delivers the gene for a vaccine antigen and the gene for a TLR3 (toll-like receptor 3) ligand. The antigen selected for this program is the Ebola GP (glycoprotein) protein, which is displayed on the viral surface.

Ebola Tablet Vaccine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug